The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Real-world outcomes of talquetamab for RRMM: US Multiple Myeloma Immunotherapy Consortium
Oren Pasvolsky, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses real-world outcomes of talquetamab therapy for relapsed/refractory multiple myeloma from the US Multiple Myeloma Immunotherapy Consortium. The study found similar outcomes to the pivotal MonumenTAL-1 trial (NCT04634552), with better outcomes in patients who received talquetamab as bridging prior to CAR-T. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
